@article{ETD,
      school = {M.S.},
      author = {Dodson, Evan},
      url = {http://digitalcollections.ohsu.edu/record/43397},
      title = {Effect of reducing imaging time points in lutetium-177  vipivotide tetraxetan dosimetry},
      publisher = {Oregon Health and Science University},
      abstract = {Lutetium-177 vipivotide tetraxetan (Lu-177 PSMA-617)  therapy is an effective treatment for patients with  metastatic prostate cancer, although with potential adverse  effects to the kidneys, salivary glands, and bone marrow.  As a preventative measure for atrisk patients, dosimetry  using four SPECT/CT scans is performed with the first cycle  of Lu177 therapy. In this work, seven Lu-177 PSMA-617  dosimetry cases from patients treated at Oregon Health &  Science University with SPECT scans taken at 4 hours, 24  hours, 48 hours, and 72 hours post-injection  were  retrospectively analyzed for how omitting each of the scans  in performing dosimetry would affect reported absorbed  doses to the kidneys, liver, lungs, parotid glands, and  tumor.},
      number = {ETD},
      doi = {https://doi.org/10.6083/bpxhc43397},
      recid = {43397},
      address = {2024-06-14},
}